Charles River: Update makes finding the right tumor model more efficient

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/daizuoxin)
(Image: iStock/daizuoxin)

Related tags Immune system

Charles River has launched a new online tool to help researchers design in vitro and in vivo oncology research studies – to put the power of data in the hands of scientists, says exec.

Tumor Model Compendium web interface provides an online, easily accessible database of the company’s tumor models, Aidan Synnott, executive director, discovery oncology, Charles River, told us.

This allows researchers to find a model based on specific histology or molecular property and the ability to do combination searches across several properties makes finding the right tumor model for a study much more efficient​,” he said.

It puts the power of our data in the hands of scientists​.”

The collection includes tumor models from a range of tumor subtypes for in vivo​ and in vitro​ oncology research. It includes patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models.

The Compendium also includes human leukocyte antigen (HLA) subtyping data, the availability of which helps researchers understand and control immune system variability, according to the company.

We’re excited that, with this update, we’re able to provide more accessible data on our tumor models, making the Compendium a powerful tool in ​in vitro as well as ​in vivo oncology research​,” said Synnott.

We’re seeing a definite shift toward ​in vitro oncology for early toxicity and patient identification, because it provides researchers a rapid and cost-effective way to test the efficacy of a compound​.”

Charles River recently acquired KWS BioTest​ to expand the company’s immunology contract research services and geographical footprint, and just last week announced​ its purchase of the non-clinical CRO MPI Research for $800m (€648m).

Last year, the company also established partnerships with OcellO​ and InSphero AG​ as part of its stated commitment to the in vitro oncology space. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more